{"title":"全身红斑狼疮患者文身安全吗？单中心研究的结果。","authors":"Francesco Natalucci, Fulvia Ceccarelli, Licia Picciariello, Giulio Olivieri, Claudia Ciancarella, Cristiano Alessandri, Fabrizio Conti","doi":"10.5826/dpc.1404a230","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Systemic Lupus Erythematosus is a pleiotropic autoimmune disease with common skin involvement. To date, only one study has investigated tattoos safety in SLE patients.</p><p><strong>Objective: </strong>We performed a single-center study to evaluate the development of local and systemic complications after tattooing in a cohort of systemic lupus erythematosus (SLE) patients. Furthermore, we tried to identify SLE patients who had expressed the will to get a tattoo and why they decided not to.</p><p><strong>Methods: </strong>Consecutive SLE patients were asked to complete a questionnaire about tattoos, including their number, features, and side effects. Open questions were proposed to non-tattooed patients to describe why they did not have tattoos.</p><p><strong>Results: </strong>One hundred ninety-two SLE patients were enrolled [M/F 21/171; median age 41 years (IQR 18)]. Almost 50% of them had at least one tattoo. Seven patients (7.4%) referred adverse reactions to tattoos; interestingly, only one patient experienced a systemic reaction, specifically the occurrence of self-limiting lymphadenopathy. The main reason for not getting a tattoo was the diagnosis of SLE.</p><p><strong>Conclusions: </strong>Our results suggest the safety of tattoos in SLE patients, as demonstrated by a low prevalence of mild adverse events.</p>","PeriodicalId":11168,"journal":{"name":"Dermatology practical & conceptual","volume":"14 4","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11619997/pdf/","citationCount":"0","resultStr":"{\"title\":\"Are Tattoos Safe in Patients with Systemic Lupus Erythematosus? Results From a Single-Center Study.\",\"authors\":\"Francesco Natalucci, Fulvia Ceccarelli, Licia Picciariello, Giulio Olivieri, Claudia Ciancarella, Cristiano Alessandri, Fabrizio Conti\",\"doi\":\"10.5826/dpc.1404a230\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Systemic Lupus Erythematosus is a pleiotropic autoimmune disease with common skin involvement. To date, only one study has investigated tattoos safety in SLE patients.</p><p><strong>Objective: </strong>We performed a single-center study to evaluate the development of local and systemic complications after tattooing in a cohort of systemic lupus erythematosus (SLE) patients. Furthermore, we tried to identify SLE patients who had expressed the will to get a tattoo and why they decided not to.</p><p><strong>Methods: </strong>Consecutive SLE patients were asked to complete a questionnaire about tattoos, including their number, features, and side effects. Open questions were proposed to non-tattooed patients to describe why they did not have tattoos.</p><p><strong>Results: </strong>One hundred ninety-two SLE patients were enrolled [M/F 21/171; median age 41 years (IQR 18)]. Almost 50% of them had at least one tattoo. Seven patients (7.4%) referred adverse reactions to tattoos; interestingly, only one patient experienced a systemic reaction, specifically the occurrence of self-limiting lymphadenopathy. The main reason for not getting a tattoo was the diagnosis of SLE.</p><p><strong>Conclusions: </strong>Our results suggest the safety of tattoos in SLE patients, as demonstrated by a low prevalence of mild adverse events.</p>\",\"PeriodicalId\":11168,\"journal\":{\"name\":\"Dermatology practical & conceptual\",\"volume\":\"14 4\",\"pages\":\"\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-10-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11619997/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatology practical & conceptual\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5826/dpc.1404a230\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology practical & conceptual","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5826/dpc.1404a230","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}
Are Tattoos Safe in Patients with Systemic Lupus Erythematosus? Results From a Single-Center Study.
Introduction: Systemic Lupus Erythematosus is a pleiotropic autoimmune disease with common skin involvement. To date, only one study has investigated tattoos safety in SLE patients.
Objective: We performed a single-center study to evaluate the development of local and systemic complications after tattooing in a cohort of systemic lupus erythematosus (SLE) patients. Furthermore, we tried to identify SLE patients who had expressed the will to get a tattoo and why they decided not to.
Methods: Consecutive SLE patients were asked to complete a questionnaire about tattoos, including their number, features, and side effects. Open questions were proposed to non-tattooed patients to describe why they did not have tattoos.
Results: One hundred ninety-two SLE patients were enrolled [M/F 21/171; median age 41 years (IQR 18)]. Almost 50% of them had at least one tattoo. Seven patients (7.4%) referred adverse reactions to tattoos; interestingly, only one patient experienced a systemic reaction, specifically the occurrence of self-limiting lymphadenopathy. The main reason for not getting a tattoo was the diagnosis of SLE.
Conclusions: Our results suggest the safety of tattoos in SLE patients, as demonstrated by a low prevalence of mild adverse events.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
